• Issue

    Precision Radiation Oncology: Volume 6, Issue 1

    1-95
    March 2022

ISSUE INFORMATION

Open Access

Issue Information

  • Pages: 1-3
  • First Published: 30 March 2022

ORIGINAL ARTICLES

Open Access

Investigation of the systemic inflammatory index as a predictor of downstaging in locally advanced rectal cancer patients with preoperative chemoradiation

  • Pages: 32-38
  • First Published: 03 March 2022
Investigation of the systemic inflammatory index as a predictor of downstaging in locally advanced rectal cancer patients with preoperative chemoradiation

Purpose: To find the correlations between blood systemic inflammatory biomarkers at three treatment time points and clinical effects of neoadjuvant chemoradiotherapy (neo-CRT) through a retrospective study.

Methods: In total 101 patients with locally advanced rectal cancer (LARC) were included in the current study. Patients were divided into two groups based on the T-downstaging, among which 54 patients had T-downstaging. We used non-parametric tests to compare the differences between the variables in two groups. We performed a logistic regression analysis to evaluate the predictive value of blood systemic inflammatory biomarkers.

Results: Pre/nadir/post-systemic immune-inflammation (SII), nadir-neutrophil-to-lymphocyte ratio (NLR), nadir/post-platelet-to-lymphocyte ratio (PLR), and post-Lymphocyte (post-Lym) have differences between groups (P  $ \le $  0.05 for all). We included P  $ \le $  0.05 indicators and clinical related factors into the multivariate analysis, respectively, and we found that lower pre-SII, nadir-SII/NLR/PLR, and post-PLR were associated with better therapeutic effects (P  $ \le $  0.05).

Conclusions: The systemic inflammatory index was indicative in predicting the therapeutic effects of LARC patients after neo-CRT.

Open Access

Patterns of care in the radiotherapeutic management of head and neck cancer of unknown primary origin: in search of a standard

  • Pages: 39-45
  • First Published: 09 February 2022
Patterns of care in the radiotherapeutic management of head and neck cancer of unknown primary origin: in search of a standard

The radiotherapeutic management of head and neck cervical lymph node metastasis of unknown primary origin is highly variable. Most notably, variability exists in the extent of irradiated volumes and points to a need to the development of standardized, evidence-based guidelines.

REVIEWS

Open Access

Carbon ion radiotherapy in the management of non-small cell lung cancer

  • Pages: 69-74
  • First Published: 22 March 2022
Carbon ion radiotherapy in the management of non-small cell lung cancer

Carbon ion radiotherapy is a form of high-linear energy transfer radiation therapy that may have several theoretical advantages over traditional low-linear energy transfer therapies in the treatment of both early-stage and locally advanced non-small cell cancer. These potential advantages include the ability to achieve high intratumoral radiation doses while sparing adjacent critical structures of the mediastinum, delivering adequate radiation doses in fewer fractions, limiting/eliminating the use of concurrent cytotoxic chemotherapy, and increasing the response to immunotherapy, thereby reducing eventual metastatic spread.

Open Access

Advances in MRI-guided precision radiotherapy

  • Pages: 75-84
  • First Published: 22 January 2022
Advances in MRI-guided precision radiotherapy

This paper summarizes six recent technical advances in magnetic resonance imaging (MRI) for MRI-guided radiotherapy: MRI simulators, MRI-linear accelerator hybrid machines, MRI-only workflow, four-dimensional MRI, MRI-based radiomics, and magnetic resonance fingerprinting.

Open Access

The role of stereotactic body radiation therapy in the management of pulmonary metastases: a systematic review

  • Pages: 85-95
  • First Published: 24 March 2022
The role of stereotactic body radiation therapy in the management of pulmonary metastases: a systematic review

Stereotactic body radiation therapy is a relatively novel treatment that can be used for the management of pulmonary metastases. On examination of various survival outcomes, SBRT showed promising benefits regarding overall survival and local control, with indications for future research comparing it directly with metastasectomy.